局灶性免疫治疗相关胰腺炎在FDG PET/CT上模拟转移瘤
一例46岁转移性肺腺癌男性患者接受帕博利珠单抗治疗3周期后行FDG PET/CT,发现胰尾局灶性增大伴SUVmax 7,经皮质激素治疗并停用帕博利珠单抗后影像学消退,诊断为局灶性免疫治疗相关胰腺炎。免疫检查点抑制剂可产生FDG高摄取的独特不良反应谱,可能模拟转移性疾病。
要点
- 免疫检查点抑制剂可致局灶性胰腺炎,FDG PET/CT上可模拟转移。
- 帕博利珠单抗治疗3周期后胰尾局灶性增大伴SUVmax 7。
- 皮质激素治疗并停药后影像学消退,支持免疫相关不良反应诊断。
核心结论
- 免疫检查点抑制剂治疗后可出现FDG高摄取的局灶性胰腺炎,影像表现可模拟转移瘤。
研究设计与样本
- 单例病例报告:46岁转移性肺腺癌男性,帕博利珠单抗治疗3周期后行FDG PET/CT。
主要发现
- FDG PET/CT显示胰尾局灶性增大,SUVmax为7。
- 经皮质激素治疗并停用帕博利珠单抗后,影像学消退,诊断为局灶性免疫治疗相关胰腺炎。
关键数值与推荐
- 胰尾局灶性增大伴SUVmax 7,经皮质激素治疗并停用帕博利珠单抗后影像学消退。
临床怎么用
- 解读FDG PET/CT时需认识免疫检查点抑制剂相关FDG高摄取不良反应的影像特征,以避免误判为转移并支持及时决策治疗。
局限性
- 单例病例报告,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 46-year-old man with metastatic lung adenocarcinoma was treated with pembrolizumab. FDG PET/CT was performed after 3 cycles of treatment and revealed a focal region of pancreatic tail enlargement with an SUVmax value of 7. Following treatment with corticosteroids and discontinuation of pembrolizumab, radiological resolution was observed, and a diagnosis of focal immunotherapy-induced pancreatitis was made. A unique spectrum of FDG-avid adverse events can develop in patients treated with immune-checkpoint inhibitors that may mimic metastatic disease. Knowledge of the radiologic features of these potential imaging pitfalls is crucial among those interpreting FDG PET/CT to allow prompt and decisive treatment.
引用
- Das JP, Halpenny D, Do RK, et al. Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT. Clin Nucl Med. 2019. PMID: 31283599. doi:10.1097/RLU.0000000000002692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。